Zhongguancun supports overseas returnees

chinadaily.com.cn | Updated: Mar 26, 2021 L M S

The Zhongguancun Overseas Talent Pioneer Park has explored a full-chain innovation and entrepreneurship service system to create a unique business environment that attracts and serves overseas returnees and stimulates innovation and entrepreneurship.

InferVision Technology is an AI company. Led by Chen Kuan, who graduated from Chicago University, the enterprise has launched a COVID-19 intelligent screening and pandemic monitoring AI system. The product has not only landed in dozens of domestic hospitals, but also hospitals in North America, Europe, Japan and other countries and regions to help fight the disease.

The AI system of InferVision Technology.png

The AI system of InferVision Technology [Photo/zgcgw.beijing.gov.cn]

In November 2020, the National Medical Products Administration formally approved the pulmonary nodule AI Class III certification of InferVision. It was the first pulmonary AI Class III certification issued by the NMPA. 

So far, InferVision has become the only AI medical company in the world with four major certifications: China NMPA, EU CE, Japan PMDA and US FDA.

More than 30 percent of the entrepreneurs in Zhongguancun have studied or worked overseas. Returned entrepreneurs have become the main force of entrepreneurship in Zhongguancun.

The distribution of Zhongguancun Overseas Talent Pioneer Parks in Beijing.png

The distribution of Zhongguancun Overseas Talent Pioneer Parks in Beijing [Photo/zgcgw.beijing.gov.cn]

Since the establishment of the first overseas talent park in 1997, Zhongguancun has opened 45 such parks with a total incubation area of more than 1.4 million square meters. These areas have attracted more than 6,000 overseas start-ups, and nearly 1,600 companies have launched in these parks.

Recently, neoX Biotech, a cutting-edge technology company from an overseas talent park of Zhongguancun Life Science Park, announced the completion of a $30 million Series A financing. The company drives the research and development of new drugs with computational design.

In the past six months, neoX Biotech has built a next-generation innovative drug R&D platform based on the "AI + biophysics + high throughput" trinity, and several innovative drug R&D pipelines derived from this platform have achieved good results. 

With preclinical progress, many drugs will enter the PCC (preclinical candidate compound) stage.

Presently, Zhongguancun Overseas Talent Pioneer Park has obtained a total of 20,676 intellectual property rights and a total of 2,827 scientific and technological achievement transformation projects. 

In 2020 alone, there were 951 projects in the research phase. The total R&D investment in that year was as high as 2.04 billion yuan ($310.94 million).

On Jan 22, a special online recruitment event attracted more than 20,000 international students. 

This was a special event of the "Remaining in Zhongguancun" campaign held by Jingjin Electric in an overseas talent park. 

During the event, Jingjin Electric conducted a live broadcast to provide a resume green channel for international students, helping them pass the screening stage.

The Remain in Zhongguancun special event held by Jingjin Electric.png

The "Remain in Zhongguancun" special event held by Jingjin Electric [Photo/zgcgw.beijing.gov.cn]

Prior to this, "Remain in Zhongguancun" online recruitment activities had been held at well-known Zhongguancun companies such as Glodon, ByteDance and Cambricon, providing new technical positions for overseas students. 

The Zhongguancun Overseas Talent Pioneer Park has organized a range of activities to recruit and support high-end talents, including roadshows for overseas students' projects and talent agency stations. The park also strives to create an "overseas" entrepreneurial environment, effectively shortening the integration process of overseas talents in Zhongguancun.